Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil.

Matthaei J, Seitz T, Jensen O, Tann A, Prukop T, Tadjerpisheh S, Brockmöller J, Tzvetkov MV.

Clin Pharmacol Ther. 2018 Jun 7. doi: 10.1002/cpt.1128. [Epub ahead of print]

PMID:
29882324
2.

Assay Conditions Influence Affinities of Rat Organic Cation Transporter 1: Analysis of Mutagenesis in the Modeled Outward-Facing Cleft by Measuring Effects of Substrates and Inhibitors on Initial Uptake.

Gorboulev V, Rehman S, Albert CM, Roth U, Meyer MJ, Tzvetkov MV, Mueller TD, Koepsell H.

Mol Pharmacol. 2018 Apr;93(4):402-415. doi: 10.1124/mol.117.110767. Epub 2018 Jan 16.

PMID:
29339398
3.

Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.

Meyer MJ, Seitz T, Brockmöller J, Tzvetkov MV.

PLoS One. 2017 Dec 13;12(12):e0189521. doi: 10.1371/journal.pone.0189521. eCollection 2017.

4.

OCT1 pharmacogenetics in pain management: is a clinical application within reach?

Tzvetkov MV.

Pharmacogenomics. 2017 Nov;18(16):1515-1523. doi: 10.2217/pgs-2017-0095. Epub 2017 Oct 24. Review.

PMID:
29061087
5.

Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency.

Tzvetkov MV, Matthaei J, Pojar S, Faltraco F, Vogler S, Prukop T, Seitz T, Brockmöller J.

Clin Pharmacol Ther. 2018 May;103(5):868-878. doi: 10.1002/cpt.812. Epub 2017 Dec 8.

PMID:
28791698
6.

Erratum to: Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families.

Chen J, Brockmöller J, Seitz T, König J, Tzvetkov MV, Chen X.

Biol Chem. 2017 Jun 27;398(7):813. doi: 10.1515/hsz-2017-0129. No abstract available.

PMID:
28291733
7.

Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.

Matthaei J, Tzvetkov MV, Gal V, Sachse-Seeboth C, Sehrt D, Hjelmborg JB, Hofmann U, Schwab M, Kerb R, Brockmöller J.

Genome Med. 2016 Nov 8;8(1):119.

8.

Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption.

Stamer UM, Musshoff F, Stüber F, Brockmöller J, Steffens M, Tzvetkov MV.

Pain. 2016 Nov;157(11):2467-2475.

PMID:
27541716
9.

Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families.

Chen J, Brockmöller J, Seitz T, König J, Chen X, Tzvetkov MV.

Biol Chem. 2017 Feb 1;398(2):237-249. doi: 10.1515/hsz-2016-0236. Erratum in: Biol Chem. 2017 Jun 27;398(7):813.

PMID:
27676604
10.

Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2.

Matthaei J, Tzvetkov MV, Strube J, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R, Brockmöller J.

Clin Pharmacol Ther. 2016 Dec;100(6):606-616. doi: 10.1002/cpt.444. Epub 2016 Sep 23.

PMID:
27509179
11.

OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics.

Matthaei J, Kuron D, Faltraco F, Knoch T, Dos Santos Pereira JN, Abu Abed M, Prukop T, Brockmöller J, Tzvetkov MV.

Clin Pharmacol Ther. 2016 Jun;99(6):633-41. doi: 10.1002/cpt.317. Epub 2016 Jan 12.

PMID:
26659468
12.

High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.

Hasheminasab SM, Tzvetkov MV, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, Steffens M, Scholl C, Hichert V, Seufferlein T, Brockmöller J, Stingl JC.

Pharmacogenomics. 2015;16(14):1605-19. doi: 10.2217/pgs.15.97. Epub 2015 Sep 30.

PMID:
26419366
13.

Heritability of metoprolol and torsemide pharmacokinetics.

Matthaei J, Brockmöller J, Tzvetkov MV, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R.

Clin Pharmacol Ther. 2015 Dec;98(6):611-21. doi: 10.1002/cpt.258. Epub 2015 Oct 19.

PMID:
26344676
14.

Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1.

Seitz T, Stalmann R, Dalila N, Chen J, Pojar S, Dos Santos Pereira JN, Krätzner R, Brockmöller J, Tzvetkov MV.

Genome Med. 2015 Jun 18;7(1):56. doi: 10.1186/s13073-015-0172-0. eCollection 2015.

15.

Impact of mineralocorticoid receptor polymorphisms on urinary electrolyte excretion with and without diuretic drugs.

Dalila N, Brockmöller J, Tzvetkov MV, Schirmer M, Haubrock M, Vormfelde SV.

Pharmacogenomics. 2015 Jan;16(2):115-27. doi: 10.2217/pgs.14.163.

PMID:
25616098
16.

The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.

Dos Santos Pereira JN, Tadjerpisheh S, Abu Abed M, Saadatmand AR, Weksler B, Romero IA, Couraud PO, Brockmöller J, Tzvetkov MV.

AAPS J. 2014 Nov;16(6):1247-58. doi: 10.1208/s12248-014-9649-9. Epub 2014 Aug 26.

17.

PharmGKB summary: tramadol pathway.

Gong L, Stamer UM, Tzvetkov MV, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 Jul;24(7):374-80. doi: 10.1097/FPC.0000000000000057. No abstract available.

18.

Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?

Tzvetkov MV, Seitz T, Bokelmann K, Mueller T, Brockmöller J, Koepsell H.

Blood. 2014 Feb 27;123(9):1427-9. doi: 10.1182/blood-2013-11-535864. No abstract available.

19.

Genetic polymorphisms in 11β-hydroxysteroid dehydrogenase type 1 correlate with the postdexamethasone cortisol levels and bone mineral density in patients evaluated for osteoporosis.

Siggelkow H, Etmanski M, Bozkurt S, Groβ P, Koepp R, Brockmöller J, Tzvetkov MV.

J Clin Endocrinol Metab. 2014 Feb;99(2):E293-302. doi: 10.1210/jc.2013-1418. Epub 2013 Nov 27.

PMID:
24285685
20.

Polymorphic OCT1: a valid biomarker, but for which drugs?

Brockmöller J, Tzvetkov MV.

Pharmacogenomics. 2013 Dec;14(16):1933-6. doi: 10.2217/pgs.13.189. No abstract available.

PMID:
24279844
21.

Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene.

O'Brien VP, Bokelmann K, Ramírez J, Jobst K, Ratain MJ, Brockmöller J, Tzvetkov MV.

J Pharmacol Exp Ther. 2013 Oct;347(1):181-92. doi: 10.1124/jpet.113.206359. Epub 2013 Aug 6.

22.

Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration.

Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmöller J.

Biochem Pharmacol. 2013 Sep 1;86(5):666-78. doi: 10.1016/j.bcp.2013.06.019. Epub 2013 Jul 5.

23.

The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1.

Saadatmand AR, Tadjerpisheh S, Brockmöller J, Tzvetkov MV.

Biochem Pharmacol. 2012 May 15;83(10):1427-34. doi: 10.1016/j.bcp.2012.01.032. Epub 2012 Feb 10.

PMID:
22342776
24.

Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.

Tzvetkov MV, Behrens G, O'Brien VP, Hohloch K, Brockmöller J, Benöhr P.

Pharmacogenomics. 2011 Oct;12(10):1417-27. doi: 10.2217/pgs.11.93. Epub 2011 Sep 8.

PMID:
21902499
25.

Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.

Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC, Brockmöller J.

Clin Pharmacol Ther. 2011 Jul;90(1):143-50. doi: 10.1038/clpt.2011.56. Epub 2011 May 11.

PMID:
21562485
26.

Relation between renal dysfunction requiring renal replacement therapy and promoter polymorphism of the erythropoietin gene in cardiac surgery.

Popov AF, Schulz EG, Schmitto JD, Coskun KO, Tzvetkov MV, Kazmaier S, Zimmermann J, Schöndube FA, Quintel M, Hinz J.

Artif Organs. 2010 Nov;34(11):961-8. doi: 10.1111/j.1525-1594.2010.01108.x.

PMID:
21092038
27.

Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron.

Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmöller J.

Pharmacogenomics J. 2012 Feb;12(1):22-9. doi: 10.1038/tpj.2010.75. Epub 2010 Oct 5.

PMID:
20921968
28.

Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies.

Tzvetkov MV, Meineke I, Sehrt D, Vormfelde SV, Brockmöller J.

Pharmacogenomics. 2010 Mar;11(3):449-57. doi: 10.2217/pgs.10.14.

PMID:
20235797
29.

A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma.

Hoffmann M, Schirmer MA, Tzvetkov MV, Kreuz M, Ziepert M, Wojnowski L, Kube D, Pfreundschuh M, Trümper L, Loeffler M, Brockmöller J; German Study Group for High-Grade Non-Hodgkin Lymphoma.

Cancer Res. 2010 Mar 15;70(6):2328-38. doi: 10.1158/0008-5472.CAN-09-2388. Epub 2010 Mar 9.

30.

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolić I, Koepsell H, Brockmöller J.

Clin Pharmacol Ther. 2009 Sep;86(3):299-306. doi: 10.1038/clpt.2009.92. Epub 2009 Jun 17.

PMID:
19536068
31.

Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines.

Kühne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmöller J.

Biochem Pharmacol. 2009 Jul 1;78(1):45-53. doi: 10.1016/j.bcp.2009.03.026. Epub 2009 Apr 5.

PMID:
19447222
32.

Bioinformatic and functional analysis of TGFBR1 polymorphisms.

Schirmer MA, Hoffmann AO, Campean R, Janke JH, Zidek LM, Hoffmann M, Kruse M, Sehrt D, Tzvetkov MV, Rave-Fränk M, Brockmöller J.

Pharmacogenet Genomics. 2009 Apr;19(4):249-59. doi: 10.1097/FPC.0b013e32831cb5a7.

PMID:
19214138
33.

Characterization of transcriptional regulation of 5-HT3B in rat PC-12 cells: the role of glucocorticoids.

Bokelmann K, Brockmoeller J, Tzvetkov MV.

Int J Clin Pharmacol Ther. 2009 Jan;47(1):36-7. No abstract available.

PMID:
19203532
34.

Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment.

Tzvetkov MV, Brockmöller J, Roots I, Kirchheiner J.

Pharmacogenet Genomics. 2008 Jun;18(6):495-506. doi: 10.1097/FPC.0b013e3282fb02cb.

PMID:
18496129
35.

Phytate utilization by genetically engineered lysine-producing Corynebacterium glutamicum.

Tzvetkov MV, Liebl W.

J Biotechnol. 2008 Apr 30;134(3-4):211-7. doi: 10.1016/j.jbiotec.2008.02.005. Epub 2008 Feb 16.

PMID:
18374441
36.

Functional characterization of a -100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene.

Meineke C, Tzvetkov MV, Bokelmann K, Oetjen E, Hirsch-Ernst K, Kaiser R, Brockmöller J.

Pharmacogenet Genomics. 2008 Mar;18(3):219-30. doi: 10.1097/FPC.0b013e3282f51092.

PMID:
18300944
37.

Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.

Brockmöller J, Tzvetkov MV.

Eur J Clin Pharmacol. 2008 Feb;64(2):133-57. doi: 10.1007/s00228-007-0424-z. Epub 2008 Jan 26. Review.

38.

A peroxisome proliferator-activated receptor gamma-retinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription.

Krätzner R, Fröhlich F, Lepler K, Schröder M, Röher K, Dickel C, Tzvetkov MV, Quentin T, Oetjen E, Knepel W.

Mol Pharmacol. 2008 Feb;73(2):509-17. Epub 2007 Oct 25.

39.

Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine.

Tzvetkov MV, Meineke C, Oetjen E, Hirsch-Ernst K, Brockmöller J.

Gene. 2007 Jan 15;386(1-2):52-62. Epub 2006 Aug 23.

PMID:
17010535
40.

Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells.

Kersting G, Tzvetkov MV, Huse K, Kulle B, Hafner V, Brockmöller J, Wojnowski L.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):21-30. Epub 2006 Sep 7.

PMID:
16957942
41.

Application of genomewide SNP arrays for detection of simulated susceptibility loci.

Kulle B, Schirmer M, Toliat MR, Suk A, Becker C, Tzvetkov MV, Brockmöller J, Bickeböller H, Hasenfuss G, Nürnberg P, Wojnowski L.

Hum Mutat. 2005 Jun;25(6):557-65.

PMID:
15880731
42.

Genome-wide single-nucleotide polymorphism arrays demonstrate high fidelity of multiple displacement-based whole-genome amplification.

Tzvetkov MV, Becker C, Kulle B, Nürnberg P, Brockmöller J, Wojnowski L.

Electrophoresis. 2005 Feb;26(3):710-5.

PMID:
15690424

Supplemental Content

Loading ...
Support Center